(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Virtu Financial, Inc. (NASDAQ:VIRT), Littelfuse, Inc. (NASDAQ:LFUS), Gogo Inc. (NASDAQ:GOGO), Brookfield Asset Management Inc. (NYSE:BAM), Protalix BioTherapeutics, Inc. (NYSE:PLX), and Halozyme Therapeutics, Inc. (NASDAQ:HALO) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed June 11th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

VIRTU FINANCIAL, INC. (VIRT) REPORT OVERVIEW

Virtu Financial's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Virtu Financial reported revenue of $815.05MM vs $147.29MM (up 453.38%) and basic earnings per share $1.89 vs $0.10 (up 1,790.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Virtu Financial reported revenue of $1,027.98MM vs $702.27MM (up 46.38%) and basic earnings per share $0.03 vs $0.83 (down 96.39%). Virtu Financial is expected to report earnings on August 14th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.13. The estimated EPS forecast for the next fiscal year is $2.22 and is expected to report on February 14th, 2019.

For the three months ended March 31st, 2018 vs March 31st, 2017, Littelfuse reported revenue of $417.81MM vs $285.44MM (up 46.37%) and basic earnings per share $1.48 vs $1.71 (down 13.45%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Littelfuse reported revenue of $1,221.53MM vs $1,056.16MM (up 15.66%) and basic earnings per share $5.27 vs $4.63 (up 13.82%). Littelfuse is expected to report earnings on August 1st, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $2.10. The estimated EPS forecast for the next fiscal year is $10.57 and is expected to report on January 30th, 2019.

For the three months ended March 31st, 2018 vs March 31st, 2017, Gogo reported revenue of $231.83MM vs $165.41MM (up 40.16%) and basic earnings per share -$0.34 vs -$0.52. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Gogo reported revenue of $699.09MM vs $596.55MM (up 17.19%) and basic earnings per share -$2.17 vs -$1.58. Gogo is expected to report earnings on August 6th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.56. The estimated EPS forecast for the next fiscal year is -$1.98 and is expected to report on February 28th, 2019.

For the three months ended March 31st, 2018 vs March 31st, 2017, Protalix BioTherapeutics reported revenue of $4.55MM vs $2.89MM (up 57.60%) and basic earnings per share -$0.06 vs -$0.48. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Protalix BioTherapeutics reported revenue of $19.24MM vs $9.20MM (up 109.17%) and basic earnings per share -$0.65 vs -$0.29. Protalix BioTherapeutics is expected to report earnings on August 8th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.06. The estimated EPS forecast for the next fiscal year is -$0.07 and is expected to report on March 5th, 2019.

For the three months ended March 31st, 2018 vs March 31st, 2017, Halozyme Therapeutics reported revenue of $30.87MM vs $29.57MM (up 4.41%) and basic earnings per share -$0.19 vs -$0.26. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Halozyme Therapeutics reported revenue of $316.61MM vs $146.69MM (up 115.84%) and basic earnings per share $0.46 vs -$0.81. Halozyme Therapeutics is expected to report earnings on August 14th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.23. The estimated EPS forecast for the next fiscal year is -$0.64 and is expected to report on February 19th, 2019.

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

More articles related to:

Newswire Distribution Network & Management

About Us

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.